STAAR Surgical to Participate in BTIG Ophthalmology Day
STAAR Surgical Company (NASDAQ: STAA) has announced its participation in the 4th Annual BTIG Ophthalmology Day. The company's Chair of the Board, President and CEO, Thomas G. Frinzi, will engage in investor meetings and a fireside chat scheduled for December 2, 2024, at 4:00 p.m. ET. STAAR Surgical, with over 40 years in ophthalmic surgery, specializes in developing implantable lenses, particularly the EVO ICL™ product line for myopia, astigmatism and presbyopia. The company has sold more than 3,000,000 ICLs globally and markets these lenses in over 75 countries.
STAAR Surgical Company (NASDAQ: STAA) ha annunciato la sua partecipazione al 4° Annuale BTIG Ophthalmology Day. Il Presidente del Consiglio, Amministratore Delegato e CEO dell'azienda, Thomas G. Frinzi, parteciperà a incontri con gli investitori e a una chiacchierata informale programmata per il 2 dicembre 2024, alle 16:00 ET. STAAR Surgical, con oltre 40 anni di esperienza nella chirurgia oftalmica, si specializza nello sviluppo di lenti impiantabili, in particolare nella linea di prodotti EVO ICL™ per miopia, astigmatismo e presbiopia. L'azienda ha venduto oltre 3.000.000 di ICL a livello globale e commercializza queste lenti in oltre 75 paesi.
STAAR Surgical Company (NASDAQ: STAA) ha anunciado su participación en el 4to Día Anual de Oftalmología de BTIG. El Presidente del Consejo, Presidente y CEO de la empresa, Thomas G. Frinzi, se reunirá con inversores y participará en una charla informal programada para el 2 de diciembre de 2024, a las 4:00 p.m. ET. STAAR Surgical, con más de 40 años en cirugía oftálmica, se especializa en el desarrollo de lentes implantables, particularmente en la línea de productos EVO ICL™ para miopía, astigmatismo y presbicia. La empresa ha vendido más de 3.000.000 de ICL a nivel mundial y comercializa estas lentes en más de 75 países.
STAAR Surgical Company (NASDAQ: STAA)는 제4회 BTIG 안과의 날에 참여한다고 발표했습니다. 회사의 이사회 의장, 사장 및 CEO인 Thomas G. Frinzi는 2024년 12월 2일 오후 4시 ET로 예정된 투자자 회의 및 대화에 참여할 예정입니다. STAAR Surgical는 40년 이상의 안과 수술 경험을 바탕으로, 주로 근시, 난시 및 노안 치료를 위한 EVO ICL™ 제품 라인의 이식 렌즈 개발에 특화되어 있습니다. 이 회사는 전 세계적으로 3,000,000개 이상의 ICL을 판매하였으며, 75개국 이상에서 이 렌즈를 판매하고 있습니다.
STAAR Surgical Company (NASDAQ: STAA) a annoncé sa participation à la 4ème Journée Annuelle BTIG d'Ophthalmologie. Le Président du Conseil, Président et CEO de l'entreprise, Thomas G. Frinzi, participera à des réunions avec des investisseurs et à une discussion informelle prévue pour le 2 décembre 2024 à 16h00 ET. STAAR Surgical, forte de plus de 40 ans d'expérience en chirurgie ophtalmique, se spécialise dans le développement de lentilles implantables, en particulier la gamme de produits EVO ICL™ pour la myopie, l'astigmatisme et la presbytie. La société a vendu plus de 3.000.000 d'ICL dans le monde entier et commercialise ces lentilles dans plus de 75 pays.
STAAR Surgical Company (NASDAQ: STAA) hat seine Teilnahme am 4. jährlichen BTIG Augenheiltag bekannt gegeben. Der Vorsitzende des Unternehmens, Präsident und CEO, Thomas G. Frinzi, wird an Investoren-Meetings und einem informellen Gespräch teilnehmen, das für den 2. Dezember 2024 um 16:00 Uhr ET geplant ist. STAAR Surgical spezialisiert sich mit über 40 Jahren Erfahrung in der Augenchirurgie auf die Entwicklung von implantierbaren Linsen, insbesondere der EVO ICL™ Produktlinie zur Behandlung von Kurzsichtigkeit, Astigmatismus und Alterssichtigkeit. Das Unternehmen hat weltweit mehr als 3.000.000 ICL verkauft und vermarktet diese Linsen in über 75 Ländern.
- None.
- None.
Event: 4th Annual BTIG Ophthalmology Day
Management Attendee: Thomas G. Frinzi, Chair of the Board, President and CEO
Date: Monday, December 2, 2024
Fireside Chat: 4:00 p.m. ET / 1:00 p.m. PT
Location: Attendance by invitation only from BTIG, the sponsoring brokerage firm.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241125619399/en/
Investors & Media
Brian Moore
Vice President, Investor Relations and Corporate Development
(626) 303-7902, Ext. 3023
bmoore@staar.com
Source: STAAR Surgical Company
FAQ
When is STAAR Surgical (STAA) participating in the BTIG Ophthalmology Day 2024?
How many ICL lenses has STAAR Surgical (STAA) sold to date?
In how many countries does STAAR Surgical (STAA) market its ICL lenses?
What types of eye conditions does STAAR Surgical's (STAA) EVO ICL treat?
